중동 및 아프리카 월경통 치료 시장 – 2028년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

중동 및 아프리카 월경통 치료 시장 – 2028년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Jan 2021
  • MEA
  • 350 Pages
  • 테이블 수: 231
  • 그림 수: 43

>중동 및 아프리카 월경통 치료 시장, 유형별(1차성 월경통, 2차성 월경통), 치료 유형(약물, 요법, 수술, 기타), 처방 방식(처방전 없이, 처방), 투여 경로(경구, 비경구, 임플란트, 기타), 최종 사용자(병원, 전문 센터, 외래 수술 센터, 기타), 유통 채널(약국, 소매 판매, 직접 입찰, 기타), 국가(사우디 아라비아, 남아프리카, UAE, 이스라엘, 쿠웨이트, 이집트, 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측

중동 및 아프리카 월경통 치료 시장

시장 분석 및 통찰력: 중동 및 아프리카 월경통 치료 시장

월경통 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 6.2%의 CAGR로 성장하고 있으며 2028년까지 2억 1,010만 달러에 도달할 것으로 예상한다고 분석합니다. 제약 산업의 제조 공장에 대한 관심 증가와 이 지역의 월경 질환 유병률 증가는 예측 기간 동안 월경통 치료 시장 수요를 촉진하는 주요 요인입니다.

월경통은 신체 하복부에 느껴지는 경련과 욱신거리는 통증입니다. 많은 여성들이 월경 전후에 월경통을 겪습니다. 일부 여성에게는 월경통이 흔한 반면, 다른 여성에게는 월경통이 성가시고 매우 심해서 매달 며칠 동안 일상 생활을 방해합니다. 월경통의 증상은 월경 1~3일 전에 시작되는 통증으로, 월경이 시작된 후 24시간에 최고조에 달하고 2~3일 후에 가라앉으며 둔함, 지속적인 통증, 메스꺼움, 두통, 현기증, 설사 등이 있습니다.

월경통 치료는 월경통에 대한 효과적인 치료에 대한 필요성이 증가함에 따라 제조업체가 시장에 신제품을 출시하는 데 영향을 미치고, 이는 수요를 증가시키고, 정부와 제약 산업의 이니셔티브가 증가함에 따라 월경통 치료 시장이 성장합니다. 대체 요법의 사용은 월경통 치료 시장 성장에 도전이 됩니다.

현재, 제조업체가 새롭고 혁신적인 기술을 개발할 수 있는 경쟁 우위를 만들어 줄 것으로 기대되는 인식 프로그램이 진행 중입니다. 게다가, 이러한 인식 프로그램은 또한 월경통 치료 시장에서 다양한 다른 기회를 제공할 것으로 기대됩니다. 그러나 전통적인 치료법의 존재는 예측 기간 동안 월경통 치료 시장 성장을 제한할 것으로 예상됩니다.

월경통 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 월경통 치료 시장 시나리오를 이해하려면 Data ridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.

중동 및 아프리카 월경통 치료 시장

월경통 치료 시장 범위 및 시장 규모

월경통 치료 시장은 유형, 치료 유형, 처방 방식, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

  • 유형에 따라 월경통 치료 시장은 원발성 월경통과 이차성 월경통으로 구분됩니다. 2021년에는 원발성 월경통 세그먼트가 월경통 치료 시장을 지배하고 있는데, 중동과 아프리카의 여성들이 월경 중 월경통을 겪거나 겪고 있기 때문입니다.
  • 치료 유형에 따라 월경통 치료 시장은 약물, 요법, 수술 및 기타로 세분화됩니다. 2021년에는 약물 부문이 월경통 치료 시장을 지배하고 있는데, 비스테로이드성 항염제와 복합 경구 피임약이 월경통에 대한 1차 치료법이기 때문입니다.
  • 처방 방식에 따라 월경통 치료 시장은 처방과 일반 의약품으로 세분화됩니다. 2021년에는 일반 의약품 부문이 월경통 치료 시장을 지배하고 있는데, 대부분의 약물이 제네릭으로 제공되고 제약 제품을 아무런 방해 없이 공급함으로써 광고의 미덕으로 대중의 인지도를 높이고 있기 때문입니다.
  • 투여 경로에 따라 월경통 치료 시장은 경구, 비경구, 임플란트 및 기타로 세분화됩니다. 2021년에는 경구 세그먼트가 월경통 치료 시장을 지배하고 있는데, 경구 세그먼트가 첫 번째 치료 라인으로 간주되기 때문입니다.
  • 최종 사용자를 기준으로 월경통 치료 시장은 병원, 외래 수술 센터 , 전문 센터 등으로 세분화됩니다. 2021년에는 병원 부문이 월경통 치료 시장을 지배하고 있는데, 대부분의 환자가 폐경 증상을 겪고 있어 적절한 진단과 치료를 받기 위해 병원을 방문하기 때문입니다.
  • 유통 채널을 기준으로 월경통 치료 시장은 직접 입찰, 소매 판매, 약국 및 기타로 세분화됩니다. 2021년에는 약국 부문이 월경통 치료 시장을 지배하고 있는데, 약국에서 판매되는 다양한 의약품이 환자의 필요와 수요에 따라 제공되기 때문입니다.

중동 및 아프리카 월경통 치료 시장 국가 수준 분석

중동 및 아프리카 월경통 치료 시장을 분석하고, 위에 언급된 대로 국가, 유형, 치료 유형, 처방 방식, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.

중동 및 아프리카 생리통 치료 시장 보고서에서 다루는 국가는 사우디 아라비아, 남아프리카공화국, UAE, 이스라엘, 쿠웨이트, 이집트와 기타 중동 및 아프리카 국가입니다.

중동 및 아프리카 월경통 치료 시장에서 처방 모드 세그먼트는 이 지역 환자들이 OTC 월경통 치료를 많이 채택함에 따라 지배적일 것으로 예상됩니다. 사우디 아라비아는 중동 및 아프리카 월경통 치료 시장을 지배하고 있으며 이 지역의 주요 시장 참여자들의 입지가 커지면서 성장을 이끌고 있습니다. 남아프리카는 의료비 지출이 증가함에 따라 두 번째로 높은 시장 점유율을 차지하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

제조업체의 전략적 이니셔티브는 월경통 치료 시장의 플레이어에게 새로운 기회를 창출합니다.

월경통 치료 시장은 또한 월경통 치료 판매와 함께 미용 산업의 모든 국가적 성장에 대한 자세한 시장 분석, 월경통 치료 발전의 영향, 월경통 치료 시장에 대한 지원과 함께 규제 시나리오의 변화를 제공합니다. 이 데이터는 2011년부터 2019년까지의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 월경통 치료 시장 점유율 분석

월경통 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 생명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 월경통 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

중동 및 아프리카 월경통 치료 시장 보고서를 다루는 주요 기업으로는 Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Mylan NV(Viatris Inc.의 일부), Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., LIVIA, Janssen Pharmaceuticals, Inc.(Johnson & Johnson Services, Inc.의 자회사), Sun Pharmaceutical Industries Ltd. 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하면서 생리통 치료 시장도 활성화되고 있습니다.

예를 들어,

  • 2020년 10월, Bayer AG는 첫 번째 글로벌 크리에이티브 협의회를 출범시켰습니다. 이 출범의 기본 목적은 소비자 건강 산업의 기준을 높이는 것입니다. 이 출범은 헬스케어 시장에서 회사의 입지를 강화할 것으로 예상됩니다.

시장 참여자들의 협력, 합작투자 및 기타 전략은 월경통 치료 시장에서 회사 시장을 확대하고 있으며, 이를 통해 기업들은 월경통 치료에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PIPELINE ANALYSIS

4.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS

5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS

6 PREMIUM INSIGHTS

6.1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE

6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS

6.2 MARKETING EXPENSES

6.3 PAYERS:

6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:

7 EPIDEMIOLOGY

8 COVID-19 IMPACT ON MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19

8.5 CONCLUSION

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 GROWING PREVALENCE OF DYSMENORRHEA

9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS

9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES

9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE

9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS

9.2 RESTRAINTS

9.2.1 PRODUCT RECALLS

9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN

9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY

9.3 OPPORTUNITIES

9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA

9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

9.3.3 RISING DISPOSABLE INCOME

9.4 CHALLENGES

9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT

9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT

9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES

10 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE

10.1 OVERVIEW

10.2 PRIMARY DYSMENORRHEA

10.3 SECONDARY DYSMENORRHEA

11 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 FIRST LINE TREATMENT

11.2.1.1 Nonhormonal Therapy

11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs

11.2.1.1.1.1 Ibuprofen

11.2.1.1.1.2 Naproxen

11.2.1.1.1.3 Celecoxib

11.2.1.1.1.4 Mefenamic Acid

11.2.1.1.1.5 Meclofenamate

11.2.1.1.2 Acetaminophen

11.2.1.2 Hormonal Replacement Therapy y

11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)

11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol

11.2.1.2.1.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2 Extended-Cycle Oral Contraceptives

11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol

11.2.1.2.2.2 Others

11.2.1.2.3 Other

11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol

11.2.1.2.3.2 Etonogestrel Implant

11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System

11.2.1.2.3.4 Medroxyprogesterone Shot

11.2.1.3 Diuretic

11.2.1.3.1 Spironolactone

11.2.1.3.2 Ammonium Chloride

11.2.1.4 Antidepressants

11.2.2 SECOND LINE TREATMENT

11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy

11.2.2.2 Ammonium Chloride

11.3 THERAPY

11.3.1 HEAT THERAPY

11.3.1.1 Patch

11.3.1.2 Wrap

11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)

11.3.2 BEHAVIORAL COUNSELING

11.3.2.1 Desensitization-Based Procedures

11.3.2.2 Coping Strategies

11.3.2.3 Imagery

11.3.2.4 Hypnotherapy

11.3.2.5 Others

11.3.3 DIET AND VITAMINS

11.3.3.1 Vitamin E

11.3.3.2 Vitamin B

11.3.3.3 Vitamin D

11.3.3.4 Others

11.4 SURGERY

11.4.1 ENDOMETRIAL ABLATION

11.4.2 HYSTERECTOMY

11.5 OTHERS

12 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION

12.1 OVERVIEW

12.2 OVER THE COUNTER

12.3 PRESCRIPTION

13 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLETS

13.2.2 PILLS

13.2.3 CAPSULE

13.2.4 OTHERS

13.3 PARENTERAL

13.3.1 INTRAVENOUS

13.3.2 SUBCUTANEOUS

13.3.3 OTHERS

13.4 IMPLANTS

13.5 OTHERS

14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITALS

14.3 SPECIALTY CENTERS

14.4 AMBULATORY SURGICAL CENTERS

14.5 OTHERS

15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 PHARMACIES

15.2.1 HOSPITAL

15.2.2 RETAIL

15.3 DIRECT TENDER

15.4 RETAIL SALES

15.5 OTHERS

16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY

16.1 MIDDLE EAST & AFRICA

16.1.1 SAUDI ARABIA

16.1.2 SOUTH AFRICA

16.1.3 UAE

16.1.4 ISRAEL

16.1.5 KUWAIT

16.1.6 EGYPT

16.1.7 REST OF MIDDLE EAST & AFRICA

17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 GLAXOSMITHKLINE PLC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENT

19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANLYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 ABBVIE INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 MYLAN N. V. (A PART OF VIATRIS INC.).

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 ALVOGEN

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BAYER AG

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENTS

19.8 BEURER GMBH

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENT

19.9 BIOELECTRONICS CORPORATION

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 COLOR SEVEN CO., LTD.

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 CUMBERLAND PHARMACEUTICALS INC.

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 LIVIA

19.13.1 COMPANY SNAPSHOT

19.13.2 PRODUCT PORTFOLIO

19.13.3 RECENT DEVELOPMENTS

19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MYOVANT SCIENCES LTD.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENT

19.16 NOBELPHARMA CO., LTD.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENT

19.17 OBSEVA

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 PFIZER INC.

19.18.1 COMPANY SNAPSHOT

19.18.2 REVENUE ANALYSIS

19.18.3 PRODUCT PORTFOLIO

19.18.4 RECENT DEVELOPMENTS

19.19 PMS4PMS, LLC

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENT

19.2 SANOFI

19.20.1 COMPANY SNAPSHOT

19.20.2 REVENUE ANALYSIS

19.20.3 PRODUCT PORTFOLIO

19.20.4 RECENT DEVELOPMENT

19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.21.1 COMPANY SNAPSHOT

19.21.2 REVENUE ANALYSIS

19.21.3 PRODUCT PORTFOLIO

19.21.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

표 목록

LIST OF TABLES

TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS

TABLE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 8 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 52 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 53 MIDDLE EAST & AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 MIDDLE EAST & AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 78 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 79 SAUDI ARABIA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 87 SAUDI ARABIA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 88 SAUDI ARABIA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 89 SAUDI ARABIA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 90 SAUDI ARABIA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 91 SAUDI ARABIA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 92 SAUDI ARABIA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 93 SAUDI ARABIA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 94 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 95 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 SAUDI ARABIA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 SAUDI ARABIA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 SAUDI ARABIA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 SAUDI ARABIA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 101 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 103 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 104 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 105 SOUTH AFRICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 106 SOUTH AFRICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 107 SOUTH AFRICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 108 SOUTH AFRICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 109 SOUTH AFRICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 110 SOUTH AFRICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 111 SOUTH AFRICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 112 SOUTH AFRICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 113 SOUTH AFRICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 114 SOUTH AFRICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 115 SOUTH AFRICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 116 SOUTH AFRICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 117 SOUTH AFRICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 118 SOUTH AFRICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 119 SOUTH AFRICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 120 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 121 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 122 SOUTH AFRICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 123 SOUTH AFRICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 124 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 SOUTH AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 SOUTH AFRICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 127 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 129 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 130 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 131 UAE MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 132 UAE FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 133 UAE NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 134 UAE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 135 UAE HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 136 UAE COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 137 UAE EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 138 UAE OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 139 UAE DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 140 UAE SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 141 UAE THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 142 UAE HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 143 UAE BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 144 UAE DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 145 UAE SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 146 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 147 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 UAE ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 149 UAE PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 150 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 151 UAE MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 152 UAE PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 153 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 154 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 155 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 156 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 157 ISRAEL MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 158 ISRAEL FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 159 ISRAEL NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 160 ISRAEL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 161 ISRAEL HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 162 ISRAEL COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 163 ISRAEL EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 164 ISRAEL OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 165 ISRAEL DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 166 ISRAEL SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 167 ISRAEL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 168 ISRAEL HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 169 ISRAEL BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 170 ISRAEL DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 171 ISRAEL SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 172 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 173 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 174 ISRAEL ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 175 ISRAEL PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 176 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 177 ISRAEL MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 178 ISRAEL PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 179 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 180 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 181 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 182 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 183 KUWAIT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 184 KUWAIT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 185 KUWAIT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 186 KUWAIT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 187 KUWAIT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 188 KUWAIT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 189 KUWAIT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 190 KUWAIT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 191 KUWAIT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 192 KUWAIT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 193 KUWAIT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 194 KUWAIT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 195 KUWAIT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 196 KUWAIT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 197 KUWAIT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 198 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 199 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 KUWAIT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 KUWAIT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 202 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 203 KUWAIT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 204 KUWAIT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 205 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 206 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 207 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)

TABLE 208 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)

TABLE 209 EGYPT MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 210 EGYPT FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 211 EGYPT NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 212 EGYPT NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 213 EGYPT HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 216 EGYPT OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 217 EGYPT DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 218 EGYPT SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 219 EGYPT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 220 EGYPT HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 221 EGYPT BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 222 EGYPT DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 223 EGYPT SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)

TABLE 224 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)

TABLE 225 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 226 EGYPT ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 227 EGYPT PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 229 EGYPT MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 230 EGYPT PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 231 REST OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

 

그림 목록

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION

FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028

FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET

FIGURE 14 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020

FIGURE 15 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 17 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020

FIGURE 19 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)

FIGURE 21 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020

FIGURE 23 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)

FIGURE 25 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 27 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 29 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020

FIGURE 31 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)

FIGURE 33 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 35 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 37 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 39 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 40 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 41 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 42 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)

FIGURE 43 MIDDLE EAST & AFRICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Middle East and Africa Menstrual Cramps Treatment Market size will be worth USD 201.01 million by 2028.
The Middle East and Africa Menstrual Cramps Treatment Market growth rate will be 6.2% by 2028.
The Rising pharmaceutical industries interest for the manufacturing plant and rising prevalence of menstrual diseases in the region are the growth drivers of the Middle East and Africa Menstrual Cramps Treatment Market.
The type, treatment type, mode of prescription, route of administration, end user and distribution channel are the factors on which the Middle East and Africa Menstrual Cramps Treatment Market research is based.
The major companies in the Middle East and Africa Menstrual Cramps Treatment Market are Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Mylan N. V. (a part of Viatris Inc.), Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., LIVIA, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Sun Pharmaceutical Industries Ltd.